Respiratorius AB
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
RESP | SPGR
Overview
Corporate Details
- ISIN(s):
- SE0004550192 (+2 more)
- LEI:
- 5493001YRVZ5XYFEE615
- Country:
- Sweden
- Address:
- Scheeletorget 1, 223 81 Lund
- Website:
- https://www.respiratorius.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Respiratorius AB is a pharmaceutical research and development company focused on creating innovative drug candidates. The company's primary strategic focus is on oncology, specifically developing treatments for aggressive forms of cancer like diffuse large B-cell lymphoma (DLBCL). Its lead project, VAL001, is a drug candidate intended to be used as a pre-treatment to enhance the efficacy of standard therapies. While historically involved in developing drugs for respiratory diseases such as COPD and severe asthma, Respiratorius now concentrates its efforts on its cancer pipeline. The company aims to advance its projects through clinical development and subsequent commercialization via strategic partnerships and licensing agreements.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Respiratorius AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Respiratorius AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Respiratorius AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-12-06 | Johan Drott | Other | Buy | 1,120 | N/A |
